Clinical efficacy and safety of transurethral prostate blue laser vaporization versus green laser vaporization in the treatment of benign prostatic hyperplasia with different prostate volumes: A retrospective comparative study
Abstract
This study analyzes and compares the clinical efficacy and safety of transurethral blue laser vaporization of the prostate (BL-PVP) and transurethral green laser vaporization of the prostate (GL-PVP) in the treatment of benign prostatic hyperplasia (BPH). A retrospective analysis was conducted on the clinical data of 97 patients with BPH who were treated at the Urology and Nephrology Department of Xi’an People’s Hospital (Fourth Hospital of Xi’an) from June 2022 to June 2024. Patients were divided into 2 groups based on the surgical technique: the BL-PVP group (n = 46), which underwent transurethral BL-PVP, and the GL-PVP group (n = 51), which underwent transurethral GL-PVP. Additionally, patients were further categorized based on prostate volume into group A (medium volume, 30–80 mL) and group B (large volume, >80 mL). Perioperative indices and postoperative follow-up data were compared between the 2 groups. Both the BL-PVP and GL-PVP groups demonstrated significant improvements in International Prostate Symptom Score, maximum flow rate, and postvoid residual at 1, 3, and 6 months postoperatively, with overall comparable efficacy between the 2 procedures (P < .05). The BL-PVP group showed a significant advantage in bladder irrigation time, catheter indwelling time, and length of hospital stay, particularly in patients with medium prostate volume (P < .05). Furthermore, the BL-PVP group exhibited faster recovery of urinary control in the early postoperative period, with…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.